Gilead, Merck announce from Phase 2 islatravir/lenacapavir combo study
Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational combination of ...
Gilead And Merck Report Phase 2 Results For Islatravir And Lenacapavir Combination In HIV Treatment
Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...
Daily14h
Gilead withdraws bladder cancer drug Trodelvy in US
Bengaluru: Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients ...
Business Wire18h
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapav…
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
AIDS Society Of India Urges Government To Include HIV Self-Testing In Policies
( MENAFN - IANS) New Delhi, Oct 18 (IANS) The AIDS Society of India (ASI) on Friday urged the government to include HIV ...
HIV treatment breakthroughs: Namibia's success story
Namibia has made significant strides in stemming the spread of HIV and AIDS through education and prevention. However, for people like Anna Engomba, the arrival of new, life-saving medication cannot ...
Lilly, Gilead, Amgen started at outperform by Bernstein
As for Lilly ( LLY ), Bernstein said its outperform rating “hinges on what they can do with the cash they generate from ...
FiercePharma4d
With Gilead coming fast, GSK bolsters case for long-acting HIV PrEP drug Apretude
With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...
2minutemedicine.com5d
Twice-yearly lenacapavir prevents HIV more effectively than daily F/TDF or F/TAF
In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...
Managed Healthcare Executive6d
PrEP Overview in Light of Lenacapavir Licensing Agreements
Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...
Daily Maverick on MSN6d
Efficacy of six-monthly HIV prevention jab confirmed in second major study
In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...
unaids6d
New long-acting HIV prevention options for women and girls in an era of choice
This year clinical trial results for PURPOSE 1 and 2 showed the high prevention effectiveness of the 6-monthly long-acting injectable drug, lenacapavir for cisgender adolescent girls and women, ...